Fertility preserving surgeries in cervical cancer, detailed overview using tables, mention indications as per guidelines, choice of procedure, advantages and disadvantages of all procedures. Use all latest evidence s and guidelines.
Reading File
Finding Sources
Finding Sources
Searching PubMed
"cervical cancer" AND "fertility sparing" AND "trachelectomy"
Searching PubMed
"cervical cancer" AND "fertility preservation" AND "conization"
Finding Sources
Finding Sources
Reading Article
PMID: 42114502
Reading Article
PMID: 39531915
Reading File
Reading File
Reading Article
PMID: 37795440
Reading Article
PMID: 37838671
Reading File
Reading File
Searching PubMed
"cervical cancer" AND "sentinel lymph node" AND "fertility sparing"
Searching the Web
ESGO NCCN 2024 2025 guidelines fertility sparing surgery cervical cancer trachelectomy indications
Reading Web Page
https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20251121…
Reading Article
PMID: 38674254
I now have comprehensive data from NCCN 2026, ESGO/ESHRE/ESGE 2024, multiple systematic reviews (2023-2026), and major textbooks. Let me compile the full detailed overview.
Fertility-Preserving Surgeries in Cervical Cancer: A Detailed Evidence-Based Overview
1. Background and Rationale
Approximately 40-45% of cervical cancers are diagnosed in women under 45 years of age, and a significant proportion desire future fertility. Fertility-sparing surgery (FSS) has become a well-established paradigm for carefully selected early-stage patients. The guiding principle is achieving oncologic equivalence to radical hysterectomy while preserving the uterine corpus, ovarian function, and reproductive potential.
Key governing guidelines include:
- NCCN Guidelines Version 2.2026 (Cervical Cancer)
- ESGO/ESHRE/ESGE 2024 Joint Guidelines (Lancet Oncology, Nov 2024)
- ESGO-ESTRO-ESP 2023 (surgical and lymph node staging principles)
- FIGO 2018 staging system (used throughout)
2. General Patient Selection Criteria (All FSS Procedures)
All of the following favourable criteria should ideally be met before any FSS approach is considered (ESGO/ESHRE/ESGE 2024):
| Criterion | Requirement |
|---|---|
| Histology | Squamous cell carcinoma (all grades) OR usual-type HPV-associated adenocarcinoma (all grades) |
| Contraindicated histologies | Small cell neuroendocrine carcinoma, gastric-type adenocarcinoma (adenoma malignum), carcinosarcoma - NOT suitable |
| Lymphovascular space invasion (LVSI) | Absence preferred (LVSI+ may still qualify for radical trachelectomy in selected cases) |
| Nodal status | No evidence of regional or distant metastasis |
| Tumour size | Largest dimension ≤2 cm (by imaging or clinical exam) |
| Margins | Free margins on final pathology mandatory |
| Internal os involvement | No evidence of tumour involvement of internal cervical orifice; cranial tumour extent ≥1 cm from internal os |
| Imaging | Negative MRI for locoregional disease |
| Depth of invasion | ≤10 mm on cone/LEEP (for conservative surgery criteria) |
| Patient preference | Strong, documented desire for future fertility with understanding of risks |
Centre requirement (ESGO 2024): FSS must be performed exclusively in gynaecological-oncological centres with comprehensive expertise in all types of these procedures.
Pregnancy timing (ESGO 2024): Patients should not attempt pregnancy within the first 6 months after any FSS procedure.
3. Indications by FIGO Stage: Procedure Selection Matrix
NCCN v2.2026 - Fertility-Sparing Algorithm
| FIGO Stage | Clinical Setting | Recommended FSS Procedure |
|---|---|---|
| IA1 (no LVSI) | Any | Cone biopsy with negative margins; no lymph node evaluation needed |
| IA1 (LVSI+) | Fertility desired | Cone biopsy with negative margins + SLN mapping or pelvic lymphadenectomy |
| IA2 | All, meeting conservative surgery criteria | Cone biopsy with negative margins + SLN mapping or pelvic lymphadenectomy |
| IA2-IB1 | Meeting ALL conservative surgery criteria* | Conization OR simple trachelectomy + SLN/lymphadenectomy |
| IB1 | NOT meeting conservative surgery criteria | Radical trachelectomy + SLN mapping ± pelvic lymphadenectomy |
| IB2 (select cases, 2-4 cm) | No LVSI, favourable pathology | Radical trachelectomy (abdominal approach preferred) + lymphadenectomy; neoadjuvant chemo may be considered |
*Conservative surgery criteria (NCCN/ConCerv trial/SHAPE trial): Cone biopsy with negative margins, No LVSI (preferred), squamous or usual-type adenocarcinoma grade 1-2, tumour ≤2 cm, depth of invasion ≤10 mm, negative imaging.
ESGO/ESHRE/ESGE 2024 - Stage-Specific Guidance
| Stage (FIGO 2018) | ESGO Recommended FSS |
|---|---|
| IA1 (no LVSI) | Conisation (diagnostic + therapeutic) |
| IA1 (LVSI+) | Conisation/simple trachelectomy + lymph node staging |
| IA2 | Conisation/simple trachelectomy + lymph node staging (ESGO-ESTRO-ESP protocol) |
| IB1 (LVSI-negative, tumour ≤2 cm, ConCerv criteria met) | Conisation/simple trachelectomy + lymph node staging; radical trachelectomy is an option but NOT recommended over conservative approaches |
| IB1 (LVSI-positive or not meeting ConCerv criteria) | Radical trachelectomy type B; simple trachelectomy may be considered if no deep stromal involvement and high probability of adequate endocervical margins |
| IB2 (2-4 cm) | Radical trachelectomy via abdominal approach (open or minimally invasive) ± neoadjuvant chemotherapy |
4. Detailed Procedures: Technique, Indications, Advantages and Disadvantages
4A. Cone Biopsy / Conization (Cold Knife or LEEP/LLETZ)
| Feature | Details |
|---|---|
| Technique | Removal of a cone-shaped portion of the ectocervix and endocervix with cold knife (CKC) or electrosurgical loop (LEEP/LLETZ); endocervical curettage (ECC) performed for margin assessment |
| FIGO stage | IA1 (no LVSI), IA2, and select IB1 meeting ALL conservative surgery criteria |
| Tumour size | ≤2 cm; depth of invasion ≤10 mm |
| Lymph node staging | Not required for IA1/no LVSI; SLN mapping or pelvic lymphadenectomy for IA1+LVSI, IA2, IB1 |
| Cerclage | Not routinely placed after cone; however, prophylactic cerclage may be placed if cervical length is compromised |
| Uterus/Ovaries | Fully preserved |
Advantages:
| Advantage | Evidence |
|---|---|
| Least invasive approach | Outpatient or day-case procedure |
| Highest live birth rates among FSS | 80.9-84.4% LBR vs 58-68% for radical trachelectomy (Monteiro 2026 SR; Taliento 2025 SR) |
| Lowest preterm delivery rate | 18.3-31.1% vs 33.3-53.8% for radical trachelectomy (Taliento 2025; Monteiro 2026) |
| Highest pregnancy rates | 61.2-61.7% vs 36.9-50% for radical trachelectomy (Monteiro 2026; Taliento 2025) |
| Oncologically equivalent | Recurrence rate 1.9-5.5% in selected patients, not significantly different from radical surgery (Wang 2023 meta-analysis, OR 0.689; Monteiro 2026) |
| Preservation of cervical competence | Less cervical damage = better reproductive outcomes |
| No anaesthetic/surgical morbidity of radical approach | Lower complication profile |
Disadvantages:
| Disadvantage | Details |
|---|---|
| Positive margins risk | May require repeat cone or step-up to trachelectomy |
| Limited to very favourable criteria | Tumour ≤2 cm, ≤10 mm depth, no LVSI, negative margins - strict selection |
| Not suitable for all histologies | Gastric-type adenocarcinoma, neuroendocrine - absolute contraindications |
| Risk of cervical stenosis | Affects ~10-15% of patients; may impair fertility |
| Cervical insufficiency | Risk of preterm birth even with conservative cone |
| Incomplete oncologic treatment if margin positive | Requires re-excision or escalation |
4B. Simple Trachelectomy (Extrafascial / Type A)
| Feature | Details |
|---|---|
| Technique | Removal of the majority of the cervix (leaving ~5 mm of cranial cervix for cerclage placement), without parametrial resection; uterus reattached to vaginal vault; permanent cerclage placed intraoperatively |
| FIGO stage | IA1 (LVSI+), IA2, select IB1 (all conservative surgery criteria met, no LVSI or LVSI-positive without deep stromal involvement) |
| Tumour size | ≤2 cm |
| Approach | Vaginal or laparoscopic/robotic-assisted |
| Lymph node staging | SLN mapping or pelvic lymphadenectomy performed concurrently |
| ESGO 2024 note | Appropriate for IB1 LVSI-positive if no deep stromal involvement and high probability of adequate endocervical tumour-free margins |
Advantages:
| Advantage | Details |
|---|---|
| More complete cervical removal than cone | Suitable when cone margins uncertain or lesion extends to endocervix |
| Avoids radical parametrectomy | Preserves bladder/bowel innervation compared to radical trachelectomy |
| Good oncologic outcomes | Recurrence rates comparable to radical trachelectomy in selected low-risk patients (Monteiro 2026) |
| Superior reproductive outcomes vs radical trachelectomy | Higher pregnancy and live birth rates, lower preterm delivery |
| Intraoperative cerclage | Supports cervical competence and reduces preterm risk |
| Minimally invasive approach possible | Faster recovery vs open surgery |
Disadvantages:
| Disadvantage | Details |
|---|---|
| No parametrial resection | Not suitable for LVSI-positive with deep stromal involvement or high parametrial risk |
| Technically more demanding than cone | Requires experienced gynaecological oncologist |
| Cervical stenosis | Can cause infertility or dysmenorrhoea |
| Risk of cerclage-related complications | Infection, cerclage failure, cervical dystocia at delivery |
| Preterm birth risk | Higher than with cone alone, though lower than radical trachelectomy |
4C. Radical Trachelectomy (Type B - Dargent's Operation and Modifications)
Radical trachelectomy involves removal of the cervix, parametria (medial parametrium/type B), upper vagina (~1-2 cm), and supporting ligaments - equivalent to a type B radical hysterectomy - with preservation of the uterine corpus. A permanent cerclage is placed and the uterus is re-anastomosed to the vaginal vault.
Approaches to Radical Trachelectomy
| Approach | Description |
|---|---|
| Radical Vaginal Trachelectomy (RVT) | Original Dargent technique; vaginal removal of cervix + parametria with laparoscopic lymphadenectomy |
| Abdominal Radical Trachelectomy (ART) | Open laparotomy; allows wider parametrial resection; preferred for IB2 (2-4 cm) |
| Laparoscopic Radical Trachelectomy (LRT) | Minimally invasive; validated in IB1 ≤2 cm |
| Robotic Radical Trachelectomy (RoRT) | Robotic-assisted; feasibility demonstrated; operating time longer (339-387 min); blood loss lower |
Indications Matrix:
| Scenario | Preferred Approach |
|---|---|
| IB1, ≤2 cm, LVSI-positive, no conservative criteria | RVT or laparoscopic/robotic |
| IB1-IB2, 2-4 cm | ART preferred (ESGO 2024); larger parametrial margins |
| Cervical stump cancer | Laparoscopic or robotic radical trachelectomy (preferable to pelvic irradiation given bowel adhesion risk) |
| During pregnancy (selected cases, early-stage) | Considered only in select circumstances; pregnancy loss risk ~20% |
Advantages:
| Advantage | Evidence/Details |
|---|---|
| Wider oncologic margin | Removes cervix, parametria, and upper vagina; suitable for larger or LVSI-positive tumours |
| Established for IB1-IB2 | Most validated FSS for tumours >2 cm |
| Comparable overall survival to radical hysterectomy | OS 97.8-98.9% at 7 years (Monteiro 2026 SR) |
| Recurrence rate acceptable | 4.9-5.5% in stage ≤IB1; 12.1% in IB2 (Taliento 2025) |
| Pregnancy possible after | Conception rates >50%; spontaneous in majority; ~20% need ART |
| ART allows tumours up to 4 cm | NCCN 2026 notes some surgeons use 4 cm cutoff for abdominal approach |
| Open approach: better term delivery rates | Open RT: significantly better third-trimester delivery vs MIS (OR 2.68, 95% CI 1.29-5.59, Lv 2023 meta-analysis) |
Disadvantages:
| Disadvantage | Evidence/Details |
|---|---|
| Lower pregnancy rate than conservative approaches | 36.9-50% vs 61.2-61.7% for cone/simple trachelectomy (Monteiro 2026; Taliento 2025) |
| Lower live birth rate | 58.6-68.4% vs 80.9-84.4% for conservative FSS (Monteiro 2026) |
| Higher preterm delivery rate | 33.3-53.8% vs 18.3-31.1% for conservative FSS (Taliento 2025; Monteiro 2026) |
| Major surgical morbidity | Higher blood loss (especially open), longer operative time, bladder/ureter injury risk |
| Cervical incompetence | Cerclage required; risk of second-trimester loss (~10%) |
| Higher risk of infertility | Cervical stenosis, altered mucus, anatomical changes impair natural conception |
| MIS approach - caution | Open RT has better term delivery rates than MIS; MIS has lower blood loss but oncological equivalence requires careful patient selection (Lv 2023) |
| Abandonment if positive nodes | If intraoperative frozen section shows positive pelvic lymph nodes, FSS must be abandoned and patient referred for chemoradiotherapy (ESGO 2024) |
| Not for all histologies | Neuroendocrine, gastric-type adenocarcinoma - absolute contraindications |
5. Lymph Node Staging in FSS
| Scenario | Recommended Lymph Node Strategy |
|---|---|
| IA1, no LVSI | No lymph node evaluation required |
| IA1+LVSI, IA2, IB1 | SLN mapping (preferred) ± pelvic lymphadenectomy |
| IB2 | SLN mapping + full pelvic lymphadenectomy ± para-aortic sampling |
| Positive SLN on frozen section | FSS abandoned; patient proceeds to chemoradiation |
| Para-aortic lymphadenectomy | May be considered for staging (at least to inferior mesenteric artery level) but not routine |
SLN Mapping (indocyanine green or blue dye + technetium):
- Reduces lymphoedema morbidity compared to full lymphadenectomy
- Validated for tumours ≤4 cm
- Bilateral mapping required; if unilateral mapping only, contralateral full dissection recommended (ESGO 2024)
- Ultrastaging of SLNs increases detection of micrometastases and isolated tumour cells
6. Neoadjuvant Chemotherapy (NACT) + FSS for Stage IB2
For patients with IB2 (2-4 cm) tumours where FSS is strongly desired and oncologic criteria are otherwise favourable:
| Aspect | Details |
|---|---|
| Rationale | Downsizes tumour to allow conservative/radical trachelectomy with adequate margins |
| Regimen | Platinum + paclitaxel (most evidence); cisplatin-based preferred |
| Efficacy | Retrospective data suggest ART has lowest recurrence rate for IB2 post-NACT |
| ESGO 2024 status | Ongoing prospective trials (platinum/paclitaxel); currently considered investigational |
| NCCN 2026 | Select IB2 cases may undergo radical trachelectomy; NACT role acknowledged but not standard |
| Risk | Chemotherapy exposure, treatment delay if poor response, need for surgery after NACT |
7. Comparative Outcomes Summary Table
Based on the most recent systematic reviews (Monteiro 2026; Taliento 2025; Wang 2023):
| Outcome | Conization ± SLN | Simple Trachelectomy | Radical Trachelectomy (all) | Radical Trachelectomy Open | Radical Trachelectomy MIS |
|---|---|---|---|---|---|
| Recurrence rate | 1.9-5.5% | ~5% | 4.9-5.5% (IB1) / 12.1% (IB2) | Similar to MIS | Similar to open |
| 7-year overall survival | ~98.9% | ~98.9% | ~97.8% | No significant difference | No significant difference |
| Pregnancy rate | 45-61.7% | ~61% | 36.9-50% | Similar | Similar |
| Live birth rate | 80.9-84.4% | High | 58.6-68.4% | Similar | Similar |
| Preterm delivery rate | 18.3-31.1% | Moderate | 33.3-53.8% | Higher 3rd trimester delivery (OR 2.68) | Lower blood loss |
| Blood loss | Minimal | Low | Moderate-high | High (MD +139 mL vs MIS) | Lower |
| Operative time | Short | Short-moderate | Long (~240-387 min) | Shorter than robotic | Robotic: 339-387 min |
| Major morbidity | Very low | Low | Moderate | Higher | Lower |
8. Special Situations
8A. FSS in Pregnancy
- LEEP, CKC, simple trachelectomy, and radical trachelectomy have all been performed during pregnancy
- Radical trachelectomy in pregnancy: pregnancy loss risk ~20%; generally not recommended except in select circumstances (Creasy & Resnik's MFM)
- Neoadjuvant chemotherapy may be used if early-stage disease progresses during pregnancy or if tumour characteristics suggest high risk
8B. FSS After Prior Subtotal Hysterectomy / Cervical Stump Cancer
- Radical trachelectomy preferable to pelvic irradiation (avoids bowel complication risk from adhesions)
- Laparoscopic or robotic approaches reported
8C. Adenocarcinoma Considerations
- Usual-type HPV-associated adenocarcinoma (grades 1-2): acceptable for FSS under conservative criteria
- Silva pattern C adenocarcinoma: data scarce; ESGO 2024 acknowledges but notes uncertainty
- Gastric-type adenocarcinoma / adenoma malignum: absolute contraindication to FSS
- Non-HPV-associated adenocarcinomas: generally not suitable for FSS
9. Post-Procedure Surveillance
| Parameter | Guidance |
|---|---|
| Timing to attempt pregnancy | Not before 6 months post-FSS (ESGO 2024) |
| Follow-up schedule | As per ESGO-ESTRO-ESP early-stage cervical cancer guidelines |
| Cytology/HPV test | Regular cervical sampling |
| Imaging | MRI if clinical concern for recurrence |
| If recurrence | Standard treatment applicable; fertility generally lost |
10. Key Evidence Sources
| Source | Key Finding |
|---|---|
| Monteiro & Goncalves, Surg Oncol 2026 (SR, n=1487) | Less radical FSS has recurrence 5.5% vs RT 4.9%; pregnancy rate 61.2% vs 36.9%; LBR 80.9% vs 68.4%; preterm 31.1% vs 53.8% - supports surgical de-escalation in low-risk patients |
| Taliento et al., Eur J Surg Oncol 2025 (SR) | Stage ≤IB1 recurrence 4.7%, death 0.6%; IB2 recurrence 12.1%; conization LBR 84.4% vs RT 58.6%; preterm 18.3% vs 33.3% |
| Wang et al., Front Oncol 2023 (SR/MA, n=620) | Conization + pelvic node evaluation: pregnancy rate 45.4%, LBR 33.9%, recurrence 1.9%; comparable to radical surgery (OR 0.689) |
| Lv et al., BMC Pregnancy Childbirth 2023 (MA, n=1369) | Open RT: better third-trimester delivery (OR 2.68); MIS RT: less blood loss; overall survival and recurrence not significantly different |
| D'Amato et al., Medicina 2024 (SR) | FST for tumours >2 cm: 80 pregnancies, 54 live births among 443 patients - cautiously feasible |
| NCCN v2.2026 | Conization for IA1; conization/simple trachelectomy for IA2-IB1 meeting conservative criteria; radical trachelectomy for IB1 not meeting criteria and select IB2 |
| ESGO/ESHRE/ESGE 2024 (Lancet Oncology Nov 2024) | Comprehensive joint guidelines; conservative approach preferred for IB1 meeting ConCerv criteria; radical trachelectomy for IB2 via abdominal approach; NACT for select IB2 investigational |
| Sabiston Surgery 11e | Radical trachelectomy for IA1+LVSI, IA2, IB1 ≤2 cm; cerclage placed; uterus reattached to vaginal vault |
| Berek & Novak's Gynecology | RT for tumour ≤2 cm, no LVSI, no nodal metastases; robotic approach feasibility confirmed |
| Creasy & Resnik's MFM | Conception rates >50% after RT; ~20% need ART; live birth rate ~68%; all types performed in pregnancy with caution |
Key Clinical Takeaways
-
Surgical de-escalation is the trend: The 2024-2026 evidence strongly supports preferring conization or simple trachelectomy over radical trachelectomy in patients meeting all conservative surgery criteria (ConCerv/SHAPE trial criteria), as oncologic outcomes are equivalent while reproductive outcomes are substantially better.
-
Tumour size drives radicality: ≤2 cm favours conservative approach; 2-4 cm (IB2) requires radical trachelectomy via abdominal route ± NACT.
-
LVSI is the key pathological variable: LVSI-negative + all other criteria = conization or simple trachelectomy. LVSI-positive = at minimum simple trachelectomy; often radical trachelectomy.
-
Histology matters: Neuroendocrine and gastric-type adenocarcinoma are absolute contraindications to all FSS. Usual-type HPV-associated adenocarcinoma is acceptable.
-
SLN mapping: Should be routine. Positive nodes on intraoperative frozen section = abandon FSS, proceed to chemoradiation.
-
Open vs MIS for radical trachelectomy: Open approach yields better term-delivery rates; MIS has lower blood loss. Oncologic outcomes are equivalent. Patient counselling must address this trade-off.
-
Multidisciplinary, high-volume centres only: FSS for cervical cancer should not be performed in low-volume centres. All procedure types must be available.
This is a shared conversation. Sign in to Orris to start your own chat.